Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China.
Br J Ophthalmol. 2023 Aug;107(8):1092-1097. doi: 10.1136/bjophthalmol-2021-320659. Epub 2022 Mar 22.
BACKGROUND/AIM: To evaluate the clinical outcomes of penetrating canaloplasty in traumatic angle recession glaucoma at 1 year.
Patients with angle recession glaucoma underwent penetrating canaloplasty, a new Schlemm's canal-based internal drainage procedure, which creates a direct canal for flow of aqueous humour from the anterior chamber to the ostia of Schlemm's canal via a window created at the corneal scleral bed without use of antimetabolites. Postoperative intraocular pressure (IOP), number of glaucoma medications, and procedure-related complications were evaluated. Success was defined as an IOP ≤21 mm Hg without (complete) or with (qualified) use of glaucoma medication.
Forty eyes in 40 patients with angle recession glaucoma underwent successful circumferential catheterisation. The mean patient age was 42±13 years. In patients with penetrating canaloplasty that was deemed to be completely successful, the mean IOP decreased from a preoperative value of 37.8±12.3 mm Hg on 3.3±1.2 anti-glaucoma medications to 18.5±6.4 mm Hg on 1.2±1.4 medications, 14.9±4.6 mm Hg on 0.1±0.5 medications, 15.7±5.4 mm Hg on 0.1±0.4 medications and 14.8±3.6 mm Hg on 0.1±0.5 medications at 1, 3, 6 and 12 months postoperatively (p<0.05). Complete success was achieved in 35/40 eyes (87.5%) at 6 months and in 34/38 (89.5%) at 12 months. Hyphema (18/40, 45.0%) and transient IOP elevation (≥30 mm Hg, 9/40, 22.5%) were the most common postoperative complications.
Penetrating canaloplasty significantly reduces IOP and has a high success rate in angle recession glaucoma.
ChiCTR1900020511.
背景/目的:评估穿透性房角切开术治疗外伤性房角后退性青光眼 1 年后的临床疗效。
对 40 例(40 眼)房角后退性青光眼患者施行穿透性房角切开术,这是一种新的基于施莱姆氏管的内引流手术,通过在前房和施莱姆氏管口之间建立一个直接通道,使房水从前房通过角膜巩膜床的一个窗口直接流入施莱姆氏管,无需使用抗代谢药物。评估术后眼压(IOP)、降眼压药物的使用数量以及与手术相关的并发症。成功定义为眼压≤21mmHg,无需(完全)或需要(合格)使用降眼压药物。
40 例(40 眼)房角后退性青光眼患者施行穿透性房角切开术,均成功施行环形导管插入术。患者平均年龄为 42±13 岁。在穿透性房角切开术完全成功的患者中,平均眼压从术前的 37.8±12.3mmHg,使用 3.3±1.2 种抗青光眼药物,降至术后 1 个月的 18.5±6.4mmHg,使用 1.2±1.4 种药物,14.9±4.6mmHg,使用 0.1±0.5 种药物,15.7±5.4mmHg,使用 0.1±0.4 种药物,14.8±3.6mmHg,使用 0.1±0.5 种药物,术后 3、6 和 12 个月(p<0.05)。6 个月时,35/40 眼(87.5%)完全成功,12 个月时,34/38 眼(89.5%)完全成功。术后最常见的并发症是前房积血(18/40,45.0%)和短暂性眼压升高(≥30mmHg,9/40,22.5%)。
穿透性房角切开术可显著降低眼压,治疗房角后退性青光眼成功率高。
ChiCTR1900020511。